1
|
Varsi F, Ahmad S, Chakraborty M, Chandra A, Dugad SR, Goswami UD, Gupta SK, Hariharan B, Hayashi Y, Jagadeesan P, Jain A, Jain P, Kawakami S, Kojima H, Lipari P, Mahapatra S, Mohanty PK, Moharana R, Muraki Y, Nayak PK, Nonaka T, Oshima A, Pant BP, Pattanaik D, Paul S, Pradhan GS, Rameez M, Ramesh K, Reddy LV, Saha S, Sahoo R, Scaria R, Shibata S, Zuberi M. Evidence of a Hardening in the Cosmic Ray Proton Spectrum at around 166 TeV Observed by the GRAPES-3 Experiment. Phys Rev Lett 2024; 132:051002. [PMID: 38364164 DOI: 10.1103/physrevlett.132.051002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 10/16/2023] [Accepted: 01/04/2024] [Indexed: 02/18/2024]
Abstract
We present the measurement of the cosmic ray proton spectrum from 50 TeV to 1.3 PeV using 7.81×10^{6} extensive air shower events recorded by the ground-based GRAPES-3 experiment between 1 January 2014 and 26 October 2015 with a live time of 460 day. Our measurements provide an overlap with direct observations by satellite and balloon-based experiments. The electromagnetic and muon components in the shower were measured by a dense array of plastic scintillator detectors and a tracking muon telescope, respectively. The relative composition of the proton primary from the air shower data containing all primary particles was extracted using the multiplicity distribution of muons which is a sensitive observable for mass composition. The observed proton spectrum suggests a spectral hardening at ∼166 TeV and disfavors a single power law description of the spectrum up to the Knee energy (∼3 PeV).
Collapse
Affiliation(s)
- F Varsi
- Indian Institute of Technology Kanpur, Kanpur 208016, India
| | - S Ahmad
- Aligarh Muslim University, Aligarh 202002, India
| | - M Chakraborty
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - A Chandra
- Aligarh Muslim University, Aligarh 202002, India
| | - S R Dugad
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - U D Goswami
- Dibrugarh University, Dibrugarh 786004, India
| | - S K Gupta
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - B Hariharan
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - Y Hayashi
- Graduate School of Science, Osaka Metropolitan University, Sugimoto, Sumiyoshi, Osaka 558-8585, Japan
| | - P Jagadeesan
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - A Jain
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - P Jain
- Indian Institute of Technology Kanpur, Kanpur 208016, India
| | - S Kawakami
- Graduate School of Science, Osaka Metropolitan University, Sugimoto, Sumiyoshi, Osaka 558-8585, Japan
| | - H Kojima
- College of Engineering, Chubu University, Kasugai, Aichi 487-8501, Japan
| | - P Lipari
- INFN, Sezione Roma "Sapienza", Piazzale Aldo Moro 2, 00185 Roma, Italy
| | | | - P K Mohanty
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - R Moharana
- Indian Institute of Technology Jodhpur, Jodhpur 342037, India
| | - Y Muraki
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya 464-8601, Japan
| | - P K Nayak
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - T Nonaka
- Institute for Cosmic Ray Research, Tokyo University, Kashiwa, Chiba 277-8582, Japan
| | - A Oshima
- College of Engineering, Chubu University, Kasugai, Aichi 487-8501, Japan
| | - B P Pant
- Indian Institute of Technology Jodhpur, Jodhpur 342037, India
| | - D Pattanaik
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Utkal University, Bhubaneswar 751004, India
| | - S Paul
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - G S Pradhan
- Indian Institute of Technology Indore, Indore 453552, India
| | - M Rameez
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - K Ramesh
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - L V Reddy
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| | - S Saha
- Indian Institute of Technology Kanpur, Kanpur 208016, India
| | - R Sahoo
- Indian Institute of Technology Indore, Indore 453552, India
| | - R Scaria
- Indian Institute of Technology Indore, Indore 453552, India
| | - S Shibata
- College of Engineering, Chubu University, Kasugai, Aichi 487-8501, Japan
| | - M Zuberi
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
| |
Collapse
|
2
|
Mizuno Y, Shibata S, Miyagaki T, Ito Y, Taira H, Hisamoto T, Oka K, Takahashi-Shishido N, Boki H, Sato S. 501 Serum cell-free DNA as a new biomarker in cutaneous T-cell lymphoma. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
3
|
Shibata S, Sogabe S, Miwa M, Fujimoto T, Takakura N, Naotsuka A, Kitamura S, Kawamoto T, Soga T. Identification of the first highly selective inhibitor of human lactate dehydrogenase B. Sci Rep 2021; 11:21353. [PMID: 34725423 PMCID: PMC8560939 DOI: 10.1038/s41598-021-00820-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Accepted: 10/18/2021] [Indexed: 02/04/2023] Open
Abstract
Lactate dehydrogenase (LDH) catalyses the conversion of pyruvate to lactate and NADH to NAD+; it has two isoforms, LDHA and LDHB. LDHA is a promising target for cancer therapy, whereas LDHB is necessary for basal autophagy and cancer cell proliferation in oxidative and glycolytic cancer cells. To the best of our knowledge, selective inhibitors for LDHB have not yet been reported. Here, we developed a high-throughput mass spectrometry screening system using an LDHB enzyme assay by detecting NADH and NAD+. As a result, we identified a small-molecule LDHB selective inhibitor AXKO-0046, an indole derivative. This compound exhibited uncompetitive LDHB inhibition (EC50 = 42 nM). X-ray crystallography revealed that AXKO-0046 bound to the potential allosteric site away from the LDHB catalytic active site, suggesting that targeting the tetramerisation interface of the two dimers is critical for the enzymatic activity. AXKO-0046 and its derivatives can be used to validate LDHB-associated pathways in cancer metabolism.
Collapse
Affiliation(s)
- Sachio Shibata
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan.
| | - Satoshi Sogabe
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Masanori Miwa
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Takuya Fujimoto
- Chemistry, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Nobuyuki Takakura
- Chemistry, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Akihiko Naotsuka
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Shuji Kitamura
- Chemistry, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Tomohiro Kawamoto
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan.
| | - Tomoyoshi Soga
- Institute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, Japan
| |
Collapse
|
4
|
Hirano K, Harada H, Shibata S, Chou E, Naka Y, Kawaguchi K, Nishimura Y, Akayama K, Miyazaki K, Mandai K. P36.01 Primary Acinic Cell Carcinoma of Bronchial Ground Origin: A Case Report. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Fujii T, Tanaka Y, Oki H, Sato S, Shibata S, Maru T, Tanaka Y, Tanaka M, Onishi T. A new brain-penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease. J Neurochem 2021; 159:543-553. [PMID: 34398463 PMCID: PMC9293090 DOI: 10.1111/jnc.15492] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Revised: 07/30/2021] [Accepted: 08/11/2021] [Indexed: 11/26/2022]
Abstract
Gaucher disease (GD), the most common lysosomal storage disorders, is caused by GBA gene mutations resulting in glycosphingolipids accumulations in various tissues, such as the brain. While suppressing glycosphingolipid accumulation is the central strategy for treating peripheral symptoms of GD, there is no effective treatment for the central nervous system symptoms. As glycosphingolipid biosynthesis starts from ceramide glycosylation by glucosylceramide synthase (GCS), inhibiting GCS in the brain is a promising strategy for neurological GD. Herein, we discovered T-036, a potent and brain-penetrant GCS inhibitor with a unique chemical structure and binding property. T-036 does not harbor an aliphatic amine moiety and has a noncompetitive inhibition mode to the substrates, unlike other known inhibitors. T-036 exhibited sufficient exposure and a significant reduction of glucosylsphingolipids in the plasma and brain of the GD mouse model. Therefore, T-036 could be a promising lead molecule for treating central nervous system symptoms of GD.
Collapse
Affiliation(s)
- Takahiro Fujii
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Yuta Tanaka
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Hideyuki Oki
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| | - Sho Sato
- Drug Metabolism and Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Sachio Shibata
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| | - Takamitsu Maru
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| | - Yuta Tanaka
- Drug Discovery Sciences, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Maiko Tanaka
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Tomohiro Onishi
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| |
Collapse
|
6
|
Kamigaichi A, Harada H, Katsumata R, Hirano K, Matsumoto Y, Kawaguchi K, Nishimura Y, Miyazaki K, Shibata S. P05.11 Preoperative Low Muscle Quality Predicts Poor Outcomes After Surgery for Early-Stage Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
7
|
Harada H, Yagyu K, Nishida M, Kamigaichi A, Miyazaki K, Nishimura Y, Kawaguchi K, Matsumoto Y, Hirano K, Shibata S. P35.07 Analysis of Inter-Tumor Heterogeneity Among Lesions in Autopsy Cases With Untreated Lung Cancer by DNA Methylation Profiling. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Taka M, Mizuno E, Sakurai T, Shibata S, Takamatsu S, Kobayashi S, Gabata T, Kumano T. Does Reduction Of Urethral Dose In Ultra-Hypofractionated Radiotherapy For Prostate Cancer Improve Acute Genitourinary Toxicity? Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Takano S, Shibata S, Maehara M, Hobo A, Hotta N, Ozawa Y, Shibamoto Y. Reasons for Undergoing CT During Childhood: Is the Population Comparable to the Population with No Experience of CT? Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Nio Y, Ookawara M, Yamasaki M, Hanauer G, Tohyama K, Shibata S, Sano T, Shimizu F, Anayama H, Hazama M, Matsuo T. Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKA y mice. FASEB J 2020; 34:14997-15014. [PMID: 32939821 DOI: 10.1096/fj.202001084r] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 08/04/2020] [Accepted: 08/31/2020] [Indexed: 11/11/2022]
Abstract
Diabetic nephropathy (DN) is a leading cause of end-stage renal disease (ESRD). Hypertension increases kidney stress, which deteriorates function, and leads to peripheral renal vascular resistance. Long-term hypoperfusion promotes interstitial fibrosis and glomerular sclerosis, resulting in nephrosclerosis. Although hypertension and DN are frequent ESRD complications, relevant animal models remain unavailable. We generated a deoxycorticosterone acetate (DOCA)-salt hypertensive uni-nephrectomized (UNx) KKAy mouse model demonstrating hypertension, hyperglycemia, cardiac hypertrophy, kidney failure, increased urinary albumin creatinine ratio (UACR), and increased renal PDE4D and cardiac PDE5A mRNA levels. We hypothesized that the novel PDE4 selective inhibitor, compound A, and PDE5 inhibitor, sildenafil, exhibit nephroprotective, and cardioprotective effects in this new model. Compound A, sildenafil, and the angiotensin II receptor blocker, irbesartan, significantly reduced ventricular hypertrophy and pleural effusion volume. Meanwhile, compound A and sildenafil significantly suppressed the UACR, urinary kidney injury molecule-1, and monocyte chemoattractant protein-1 levels, as well as that of renal pro-fibrotic marker mRNAs, including collagen 1A1, fibronectin, and transforming growth factor-beta (TGF-β). Moreover, compound A significantly suppressed TGF-β-induced pro-fibrotic mRNA expression in vitro in all major kidney lesions, including within the glomerular mesangial region, podocytes, and epithelial region. Hence, PDE4 and PDE5 inhibitors may be promising treatments, in combination with irbesartan, for DN with hypertension as they demonstrate complementary mechanisms.
Collapse
Affiliation(s)
- Yasunori Nio
- Extra-Value Generation and General Medicine DDU, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Mitsugi Ookawara
- Extra-Value Generation and General Medicine DDU, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Midori Yamasaki
- Extra-Value Generation and General Medicine DDU, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Guido Hanauer
- Takeda Pharmaceuticals International AG, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Kimio Tohyama
- Drug Metabolism & Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Sachio Shibata
- Drug Metabolism & Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Tomoya Sano
- Drug Safety Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Fumi Shimizu
- Drug Safety Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Hisashi Anayama
- Drug Safety Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Masatoshi Hazama
- Extra-Value Generation and General Medicine DDU, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Takanori Matsuo
- Extra-Value Generation and General Medicine DDU, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| |
Collapse
|
11
|
Shibata S, Mizuno R, Mineno H. Semisupervised Deep State-Space Model for Plant Growth Modeling. Plant Phenomics 2020; 2020:4261965. [PMID: 33313556 PMCID: PMC7706328 DOI: 10.34133/2020/4261965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/12/2019] [Accepted: 03/15/2020] [Indexed: 06/12/2023]
Abstract
The optimal control of sugar content and its associated technology is important for producing high-quality crops more stably and efficiently. Model-based reinforcement learning (RL) indicates a desirable action depending on the type of situation based on trial-and-error calculations conducted by an environmental model. In this paper, we address plant growth modeling as an environmental model for the optimal control of sugar content. In the growth process, fruiting plants generate sugar depending on their state and evolve via various external stimuli; however, sugar content data are sparse because appropriate remote sensing technology is yet to be developed, and thus, sugar content is measured manually. We propose a semisupervised deep state-space model (SDSSM) where semisupervised learning is introduced into a sequential deep generative model. SDSSM achieves a high generalization performance by optimizing the parameters while inferring unobserved data and using training data efficiently, even if some categories of training data are sparse. We designed an appropriate model combined with model-based RL for the optimal control of sugar content using SDSSM for plant growth modeling. We evaluated the performance of SDSSM using tomato greenhouse cultivation data and applied cross-validation to the comparative evaluation method. The SDSSM was trained using approximately 500 sugar content data of appropriately inferred plant states and reduced the mean absolute error by approximately 38% compared with other supervised learning algorithms. The results demonstrate that SDSSM has good potential to estimate time-series sugar content variation and validate uncertainty for the optimal control of high-quality fruit cultivation using model-based RL.
Collapse
Affiliation(s)
- S. Shibata
- Graduate School of Integrated Science and Technology, Shizuoka University, 3-5-1 Johoku, Naka-ku, Hamamatsu, Shizuoka 432-8011, Japan
| | - R. Mizuno
- Graduate School of Integrated Science and Technology, Shizuoka University, 3-5-1 Johoku, Naka-ku, Hamamatsu, Shizuoka 432-8011, Japan
| | - H. Mineno
- College of Informatics, Academic Institute, Shizuoka University, 3-5-1 Johoku, Naka-ku, Hamamatsu, Shizuoka 432-8011, Japan
- JST, PRESTO, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan
| |
Collapse
|
12
|
Abstract
The synchondrosis in the cranial base is an important growth center for the craniofacial region. Abnormalities in the synchondroses affect the development of adjacent regions, including the craniofacial skeleton. Here, we report that the transcription factor TBX1, the candidate gene for DiGeorge syndrome, is expressed in mesoderm-derived chondrocytes and plays an essential and specific role in spheno-occipital synchondrosis development by inhibiting the expression of genes involved in chondrocyte hypertrophy and osteogenesis. In Tbx1-deficient mice, the spheno-occipital synchondrosis was completely mineralized at birth. TBX1 interacts with RUNX2, a master molecule of osteoblastogenesis and a regulator of chondrocyte maturation, and suppresses its transcriptional activity. Indeed, deleting Tbx1 triggers accelerated mineralization due to accelerated chondrocyte differentiation, which is associated with ectopic expression of downstream targets of RUNX2 in the spheno-occipital synchondrosis. These findings reveal that TBX1 acts as a regulator of chondrocyte maturation and osteogenesis during the spheno-occipital synchondrosis development. Thus, the tight regulation of endochondral ossification by TBX1 is crucial for the normal progression of chondrocyte differentiation in the spheno-occipital synchondrosis.
Collapse
Affiliation(s)
- N Funato
- Department of Signal Gene Regulation, Tokyo Medical and Dental University, Tokyo, Japan.,Department of Research Core, Tokyo Medical and Dental University, Tokyo, Japan
| | - D Srivastava
- Gladstone Institute of Cardiovascular Disease and Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA
| | - S Shibata
- Department of Maxillofacial Anatomy, Tokyo Medical and Dental University, Tokyo, Japan
| | - H Yanagisawa
- Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance, University of Tsukuba, Tsukuba, Japan
| |
Collapse
|
13
|
SUGAWARA H, Moniwa N, Tanno M, Miki T, Kuno A, Yano T, Sato T, Kouzu H, Shibata S, Miura T. SUN-047 PROTECTION AFFORDED BY ANGIOTENSIN II RECEPTOR ACTIVATION AGAINST ACUTE KIDNEY INJURY IS ASSOCIATED WITH UPREGULATION OF TUBULAR AUTOPHAGY. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
14
|
Shibata S, Miura T, Sugawara H. SUN-046 ROLE OF NECROPTOSIS IN CONTRAST-INDUCED NEPHROPATHY IN A RAT MODEL OF CKD AND ITS MODIFICATION BY TOLVAPTAN. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
15
|
Takahashi T, Haitani T, Tanaka F, Yamagishi T, Kawakami Y, Shibata S, Kumano H. Effects of the time-of-day (morning vs. afternoon) of implementing a combined physical and cognitive exercise program on cognitive functions and mood of older adults: A randomized controlled study. Adv Gerontol 2020; 33:595-599. [PMID: 33280348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
This study examined the effects of the time of conducting a combined physical and cognitive exercise program on cognitive functions and the mood of older adults. We randomly assigned 17 participants (8 men, 9 women, age 73,24±3,75) to the morning group (AM Group), 18 (8 men, 10 women, age 73,11±4,84) to the afternoon group (PM Group), and they completed a 12-week, dual-task exercise program in the morning or the afternoon, respectively. Moreover, the waiting-list control group consisted of 12 participants (6 men, 6 women, age 73,25±5,93). The cognitive functions and the mood of the participants were assessed before and after the program by using the Neurobehavioral Cognitive Status Examination, and the short version of the Profile of Mood States, respectively. As a result, the exercise program conducted in the afternoon had broader effects on cognitive functions (increased Repetition and Memory) than in the morning (increased Repetition), or the waiting-list control group (increased Judgment). Moreover, the program in the afternoon tended to reduce Anger-Hostility, and Fatigue. In conclusion, conducting the exercise program in the afternoon might be more effective for improving cognitive functions and the mood of older adults than in the morning. However, there was heterogeneity between the groups despite the randomization. Therefore, we suggest conducting a more rigorously controlled study using a larger sample to validate these findings.
Collapse
Affiliation(s)
- T Takahashi
- Graduate School of Human Sciences, Waseda University, Saitama, Japan 359-1192, e-mail:
- Japan Society for The Promotion of Science, Tokyo, Japan 102-0083
| | - T Haitani
- Research Institute, National Rehabilitation Center for Persons with Disabilities, Saitama, Japan 359-8555
| | - F Tanaka
- Organization for University Research Initiatives, Waseda University, Tokyo, Japan 169-8050
| | - T Yamagishi
- Faculty of Sport Sciences, Waseda University, Saitama, Japan 359-1192
| | - Y Kawakami
- Faculty of Sport Sciences, Waseda University, Saitama, Japan 359-1192
| | - S Shibata
- Faculty of Science and Engineering, Waseda University, Tokyo, Japan 169-8555
| | - H Kumano
- Faculty of Human Sciences, Waseda University, Saitama, Japan 359-1192
| |
Collapse
|
16
|
Uechi T, Shibata S, Suda T, Hata N, Hirabuki K, Tsukada T, Hirasawa A, Matsuda T. P1707Non-business hours and cold exposure independently worsen neurological outcome after out-of-hospital cardiac arrest. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
It has been known that survival rates after out-of-hospital cardiac arrest (OHCA) are lower at night than during the day. It may be explained by diurnal temperature changes.
Purpose
The purpose of the present study was to test our hypothesis that diurnal variation of the prognosis after OHCA would be independent from the ambient temperature changes.
Methods
We used the All-Japan Utstein Registry (2005–2010) combined with atmospheric temperature from the Automated Meteorological Data Acquisition System, and enrolled adult OHCA patients who had suffered from a witnessed cardiac arrest and who had been resuscitated.
The primary outcome was a favorable neurological outcome one month after OHCA and the secondary outcome was the presence of return of spontaneous circulation (ROSC) before hospital admission. Effects of business vs. non-business hours and ambient temperature on the primary and secondary outcomes were assessed with adjustment for factors that are known to potentially affect OHCA outcomes. Sub-group analysis based on the initial cardiac rhythm (VT/Vf, PEA and Asystole) was also performed.
Results
Among the 263,750 witnessed OHCA patients, neurological survival and ROSC rates were significantly increased with an adjusted odds ratio (OR) of 1.13 (95% CI 1.08–1.18) and hazard ratio (HR) of 1.06 (95% CI 1.04–1.09) for non-business hours, and OR of 1.11 (95% CI 1.05–1.17) and HR of 1.05 (95% CI 1.02–1.08) for each 20°C increase in temperature. The effects were different between business vs. non-business hours and ambient temperature dependent on the initial cardiac rhythm.
Conclusions
These findings suggest that both the outdoor temperature and business hours are independent factors for predicting neurological outcomes after OHCA with different characteristics based on the initial cardiac rhythms. Diurnal variability of prognosis after OHCA is likely to be attributable to diurnal variation of medical resources.
Collapse
Affiliation(s)
- T Uechi
- Kyorin University School of Medicine, Department of General Medicine, Tokyo, Japan
| | - S Shibata
- Kyorin University School of Medicine, Department of General Medicine, Tokyo, Japan
| | - T Suda
- Kyorin University School of Medicine, Department of General Medicine, Tokyo, Japan
| | - N Hata
- Kyorin University School of Medicine, Department of General Medicine, Tokyo, Japan
| | - K Hirabuki
- Kyorin University School of Medicine, Department of General Medicine, Tokyo, Japan
| | - T Tsukada
- Kyorin University School of Medicine, Department of General Medicine, Tokyo, Japan
| | - A Hirasawa
- Kyorin University, Faculty of Health Sciences, Department of Health and Welfare, Tokyo, Japan
| | - T Matsuda
- Kyorin University School of Medicine, Department of Traumatology and Critical Care Medicine, Tokyo, Japan
| |
Collapse
|
17
|
Morimura S, Takahashi-Shishido N, Oka T, Takahashi T, Suga H, Shibata S, Miyagaki T, Asano Y, Sato S, Sugaya M. 219 Epidermal fatty acid-binding protein is expressed by epidermis and dermal infiltrating cells in psoriasis, atopic dermatitis, and cutaneous T-cell lymphoma. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Shibata S, Yamamoto K, Sato Y, Bou S, Takamatsu S, Saga Y, Minami H, Y. M, Sasaki M, Tameshige Y, Tamamura H. Assessment of Changes of the Distance from Liver Surface to Isocenter during Proton Beam Treatment for Liver Cancer. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Iwai K, Nambu T, Dairiki R, Ohori M, Yu J, Burke K, Gotou M, Yamamoto Y, Ebara S, Shibata S, Hibino R, Nishizawa S, Miyazaki T, Homma M, Oguro Y, Imada T, Cho N, Uchiyama N, Kogame A, Takeuchi T, Kurasawa O, Yamanaka K, Niu H, Ohashi A. Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor. Sci Adv 2019; 5:eaav3660. [PMID: 31131319 PMCID: PMC6531005 DOI: 10.1126/sciadv.aav3660] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Accepted: 04/17/2019] [Indexed: 05/02/2023]
Abstract
Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell division cycle 7 (CDC7) has recently attracted attention as a target. We have developed an oral CDC7-selective inhibitor, TAK-931, as a candidate clinical anticancer drug. TAK-931 induced S phase delay and RS. TAK-931-induced RS caused mitotic aberrations through centrosome dysregulation and chromosome missegregation, resulting in irreversible antiproliferative effects in cancer cells. TAK-931 exhibited significant antiproliferative activity in preclinical animal models. Furthermore, in indication-seeking studies using large-scale cell panel data, TAK-931 exhibited higher antiproliferative activities in RAS-mutant versus RAS-wild-type cells; this finding was confirmed in pancreatic patient-derived xenografts. Comparison analysis of cell panel data also demonstrated a unique efficacy spectrum for TAK-931 compared with currently used chemotherapeutic drugs. Our findings help to elucidate the molecular mechanisms for TAK-931 and identify potential target indications.
Collapse
Affiliation(s)
- Kenichi Iwai
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Tadahiro Nambu
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Ryo Dairiki
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Momoko Ohori
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Jie Yu
- Oncology Drug Discovery Unit, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
| | - Kristine Burke
- Oncology Drug Discovery Unit, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
| | - Masamitsu Gotou
- Integrated Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Yukiko Yamamoto
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Shunsuke Ebara
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Sachio Shibata
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Ryosuke Hibino
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Satoru Nishizawa
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Tohru Miyazaki
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Misaki Homma
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Yuya Oguro
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Takashi Imada
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Nobuo Cho
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Noriko Uchiyama
- Biomolecular Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Akifumi Kogame
- DMPK Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Toshiyuki Takeuchi
- DMPK Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Osamu Kurasawa
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Kazunori Yamanaka
- Integrated Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Huifeng Niu
- Translational and Biomarker Research, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
| | - Akihiro Ohashi
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
- Oncology Drug Discovery Unit, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
- Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan
- Corresponding author.
| |
Collapse
|
20
|
Hariharan B, Chandra A, Dugad SR, Gupta SK, Jagadeesan P, Jain A, Mohanty PK, Morris SD, Nayak PK, Rakshe PS, Ramesh K, Rao BS, Reddy LV, Zuberi M, Hayashi Y, Kawakami S, Ahmad S, Kojima H, Oshima A, Shibata S, Muraki Y, Tanaka K. Measurement of the Electrical Properties of a Thundercloud Through Muon Imaging by the GRAPES-3 Experiment. Phys Rev Lett 2019; 122:105101. [PMID: 30932668 DOI: 10.1103/physrevlett.122.105101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/06/2019] [Revised: 01/21/2019] [Indexed: 06/09/2023]
Abstract
The GRAPES-3 muon telescope located in Ooty, India records rapid (∼10 min) variations in the muon intensity during major thunderstorms. Out of a total of 184 thunderstorms recorded during the interval of April 2011-December 2014, the one on December 1, 2014 produced a massive potential of 1.3 GV. The electric field measured by four well-separated (up to 6 km) monitors on the ground was used to help estimate some of the properties of this thundercloud, including its altitude and area that were found to be 11.4 km above mean sea level and ≥380 km^{2}, respectively. A charging time of 6 min to reach 1.3 GV implied the delivery of a power of ≥2 GW by this thundercloud that was moving at a speed of ∼60 km h^{-1}. This work possibly provides the first direct evidence for the generation of gigavolt potentials in thunderclouds that could also possibly explain the production of highest-energy (100 MeV) gamma rays in the terrestrial gamma-ray flashes.
Collapse
Affiliation(s)
- B Hariharan
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - A Chandra
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - S R Dugad
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - S K Gupta
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - P Jagadeesan
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - A Jain
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - P K Mohanty
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - S D Morris
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - P K Nayak
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - P S Rakshe
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - K Ramesh
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - B S Rao
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - L V Reddy
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - M Zuberi
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
| | - Y Hayashi
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
- Graduate School of Science, Osaka City University, Osaka 558-8585, Japan
| | - S Kawakami
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
- Graduate School of Science, Osaka City University, Osaka 558-8585, Japan
| | - S Ahmad
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
- Aligarh Muslim University, Aligarh 202002, India
| | - H Kojima
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
- College of Engineering, Chubu University, Kasugai, Aichi 487-8501, Japan
| | - A Oshima
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
- College of Engineering, Chubu University, Kasugai, Aichi 487-8501, Japan
| | - S Shibata
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
- College of Engineering, Chubu University, Kasugai, Aichi 487-8501, Japan
| | - Y Muraki
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Aichi 446-8601, Japan
| | - K Tanaka
- Cosmic Ray Laboratory, Raj Bhavan, Ooty 643001, India
- Graduate School of Information Sciences, Hiroshima City University, Hiroshima 731-3194, Japan
| |
Collapse
|
21
|
Muraki Y, Naito T, Tohyama K, Shibata S, Kuniyeda K, Nio Y, Hazama M, Matsuo T. Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension. Biosci Biotechnol Biochem 2019; 83:1000-1010. [PMID: 30835622 DOI: 10.1080/09168451.2019.1584520] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Pulmonary hypertension (PH) is a life-threatening lung disease. PH with concomitant lung diseases, e.g., idiopathic pulmonary fibrosis, is associated with poor prognosis. Development of novel therapeutic vasodilators for treatment of these patients is a key imperative. We evaluated the efficacy of dual activation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) using an active, small-molecule phosphodiesterase (PDE4)/PDE5 dual inhibitor (Compound A). Compound A increased both cAMP and cGMP levels in WI-38 lung fibroblasts and suppressed the expressions of type-1 collagen α1 chain and fibronectin. Additionally, compound A reduced right ventricular weight/left ventricular weight+septal weight ratio, brain natriuretic peptide expression levels in right ventricle, C─C motif chemokine ligand 2 expression levels in lung, and plasma surfactant protein D. Our data indicate that dual activation of cAMP/cGMP pathways may be a novel treatment strategy for PH.
Collapse
Affiliation(s)
- Yo Muraki
- a Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan
| | - Takako Naito
- a Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan
| | - Kimio Tohyama
- a Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan
| | - Sachio Shibata
- a Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan
| | - Kanako Kuniyeda
- a Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan
| | - Yasunori Nio
- a Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan
| | - Masatoshi Hazama
- a Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan
| | - Takanori Matsuo
- a Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan
| |
Collapse
|
22
|
Kamiya K, Koga K, Matsumoto H, Muraki Y, Shibata S. Angular and Abundance Distribution of High-energy Gamma Rays and Neutrons Simulated by GEANT4 Code for Solar Flares. EPJ Web Conf 2019. [DOI: 10.1051/epjconf/201920814005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
In the solar flare observed on June 3, 2012, high energy gamma-rays and neutrons were observed. The event includes a remarkable feature of a high neutron/gamma-ratio in the secondary particles. We have examined whether this high n/γ-ratio can be explained by simulation. As a result of simulations using the GEANT4 program, the high n/γ-ratio may be reproduced for the case that helium and other heavy ions were dominantly accelerated in the flare.
Collapse
|
23
|
Nakamura T, Ikeda M, Shibata S, Kon Y, Konuma K, Sanada T, Gonda H, Suto Y, Kobayashi K, Tamura H, Kobayashi M, Hasegawa A, Amagasa Y, Suzuki A, Fukuda M, Aoyagi C, Matsuura N, Kawashima Y, Shimura M, Takita N. Malignant lymphoma detected by screening program with esophagogastroduodenoscopy of one private screening center in Japan. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy297.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Ogawa M, Kagaya H, Shibata S, Inamoto Y, Aoyagi Y, Onogi K, Mori S, Akahori R, Saitoh E. Swallowing rounds in patients with dysphagia. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.1056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
25
|
Kagaya H, Ogawa M, Mori S, Aoyagi Y, Shibata S, Onogi K, Inamoto Y, Mori H, Saitoh E. Development of peripheral magnetic stimulation system to stimulate suprahyoid muscles. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
26
|
Mizokoshi E, Kagaya H, Aoyagi Y, Shibata S, Onogi K, Inamoto Y, Pongpipatpaiboon K, Saitoh E. Factors affecting aspiration in chew-swallow and discrete swallow in stroke patients. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Ruschel VC, Shibata S, Stolf SC, Chung Y, Baratieri LN, Heymann HO, Walter R. Eighteen-month Clinical Study of Universal Adhesives in Noncarious Cervical Lesions. Oper Dent 2018; 43:241-249. [PMID: 29676975 DOI: 10.2341/16-320-c] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To evaluate the clinical performance of Scotchbond Universal (3M Oral Care) and Prime & Bond Elect (Dentsply Sirona) in the restoration of noncarious cervical lesions (NCCLs). METHODS AND MATERIALS This was a randomized controlled clinical trial involving 63 subjects. Two hundred and three NCCLs were restored using Scotchbond Universal and Prime & Bond Elect using both an etch-and-rinse and a self-etch technique. Lesions were notch-shaped NCCLs, and the restorations were placed without any mechanical retention. Restorations were finished immediately after placement and scored with regard to retention, marginal discoloration, marginal adaptation, and secondary caries. Similar assessment of the restorations was performed 18 months after placement. Logistic regression was performed for each outcome separately with a compound symmetric variance-covariance structure assumed to consider a correlation of restorations within subjects. All analyses were conducted using SAS version 9.4 (SAS Inc). RESULTS One hundred and fifty-eight teeth (77.8% of the restorations placed) in 46 subjects (73% of subjects enrolled) were available for the 18-month follow-up. A statistically significant difference was reached only for the comparison Scotchbond Universal/self-etch (SU_SE) and Prime & Bond Elect/etch-and-rinse (PBE_E&R) groups ( p=0.01), where a restoration with SU_SE was 66% less likely to maintain a score of Alpha for marginal discoloration than a restoration performed with PBE_E&R. CONCLUSIONS Scotchbond Universal and Prime & Bond Elect presented acceptable clinical performance after 18 months of clinical service. However, Scotchbond Universal, when applied with a self-etch approach, did demonstrate a relatively high level of marginal discoloration when compared to the other groups.
Collapse
|
28
|
Mohanty P, Arunbabu K, Aziz T, Dugad S, Gupta S, Hariharan B, Jagadeesan P, Jain A, Morris S, Nayak P, Rakshe P, Ramesh K, Rao B, Zuberi M, Hayashi Y, Kawakami S, Subramanian P, Raha S, Ahmad S, Oshima A, Shibata S, Kojima H. Was the cosmic ray burst detected by the GRAPES-3 muon telescope on 22 June 2015 caused by a transient weakening of the geomagnetic field or by an interplanetary anisotropy? Int J Clin Exp Med 2018. [DOI: 10.1103/physrevd.97.082001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
29
|
Nagai K, Koshiba H, Shibata S, Hirasawa A, Ebihara T, Kozaki K. Relationship of Serum Carnitine Level with Falls and Gait Disturbance in the Elderly. J Frailty Aging 2018; 6:178-182. [PMID: 29165532 DOI: 10.14283/jfa.2017.36] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Gait disturbance and falls are serious events that can impair activities of daily living (ADL) in the elderly. On the other hand, carnitine plays essential roles in energy production, and carnitine deficiency leads to low activity levels. OBJECTIVES We examined whether a lower serum carnitine concentration was correlated with falls and gait disturbances in the elderly. DESIGN, SETTING, AND PARTICIPANTS We performed a cross-sectional study. One hundred and ninety-eight elderly patients (male, 83; female, 115; 81 ± 6 years old) were enrolled in this study. MEASUREMENTS Physical performance (hand grip strength, leg strength, walking speed, one-leg standing time, and tandem gait steps) and frailty status (The Edmonton Frail Scale: EFS) were evaluated. The serum total, free, and acylated carnitine levels were measured using an enzyme cycling method. We then investigated the associations between the serum carnitine level, history of falls, and the results of these physical examinations. RESULTS Of the 198 subjects, 56 (28%) had a history of falls within the past one year. The patients with a history of falls had lower serum total carnitine and free carnitine levels than those without a history of falls. Regarding the physical performance results, the patients with a history of falls had higher EFS scores, a weaker hand grip strength, a slower walking speed, a shorter one-leg standing time, and a smaller number of tandem gait steps than those without a history of falls. A logistic regression analysis showed that the low serum total carnitine concentration was identified as an independent factor associated with a history of falls, a slow walking speed after adjustments for age, sex and modified EFS. CONCLUSIONS A low serum carnitine level is associated with a history of falls and gait disturbances in elderly people.
Collapse
Affiliation(s)
- K Nagai
- Kumiko Nagai, Department of Geriatric Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan, Phone: +81-422-47-5511, Fax: +81-422-44-1917, E-mail:
| | | | | | | | | | | |
Collapse
|
30
|
Kojima T, Asano Y, Kurasawa O, Hirata Y, Iwamura N, Wong TT, Saito B, Tanaka Y, Arai R, Yonemori K, Miyamoto Y, Sagiya Y, Yaguchi M, Shibata S, Mizutani A, Sano O, Adachi R, Satomi Y, Hirayama M, Aoyama K, Hiura Y, Kiba A, Kitamura S, Imamura S. Discovery of novel serine palmitoyltransferase inhibitors as cancer therapeutic agents. Bioorg Med Chem 2018; 26:2452-2465. [PMID: 29669694 DOI: 10.1016/j.bmc.2018.04.008] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2017] [Revised: 04/03/2018] [Accepted: 04/03/2018] [Indexed: 12/18/2022]
Abstract
We pursued serine palmitoyltransferase (SPT) inhibitors as novel cancer therapeutic agents based on a correlation between SPT inhibition and growth suppression of cancer cells. High-throughput screening and medicinal chemistry efforts led to the identification of structurally diverse SPT inhibitors 4 and 5. Both compounds potently inhibited SPT enzyme and decreased intracellular ceramide content. In addition, they suppressed cell growth of human lung adenocarcinoma HCC4006 and acute promyelocytic leukemia PL-21, and displayed good pharmacokinetic profiles. Reduction of 3-ketodihydrosphingosine, the direct downstream product of SPT, was confirmed under in vivo settings after oral administration of compounds 4 and 5. Their anti-tumor efficacy was observed in a PL-21 xenograft mouse model. These results suggested that SPT inhibitors might have potential to be effective cancer therapeutics.
Collapse
Affiliation(s)
- Takuto Kojima
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan.
| | - Yasutomi Asano
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Osamu Kurasawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Yasuhiro Hirata
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Naoki Iwamura
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Tzu-Tshin Wong
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Bunnai Saito
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Yuta Tanaka
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Ryosuke Arai
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Kazuko Yonemori
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Yasufumi Miyamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Yoji Sagiya
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Masahiro Yaguchi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Sachio Shibata
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Akio Mizutani
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Osamu Sano
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Ryutaro Adachi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Yoshinori Satomi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Megumi Hirayama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Kazunobu Aoyama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Yuto Hiura
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Atsushi Kiba
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Shuji Kitamura
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Shinichi Imamura
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-0012, Japan.
| |
Collapse
|
31
|
Ouchi T, Morikawa S, Shibata S, Takahashi M, Yoshikawa M, Soma T, Miyashita H, Muraoka W, Kameyama K, Kawana H, Arima Y, Saya H, Okano H, Nakagawa T, Asoda S. Recurrent Spindle Cell Carcinoma Shows Features of Mesenchymal Stem Cells. J Dent Res 2018; 97:779-786. [PMID: 29494307 DOI: 10.1177/0022034518759278] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
This study investigated a case of spindle cell carcinoma (SpCC) in tongue pathological lesions. The patient experienced a local recurrence and distant metastasis after surgical intervention. Although standard chemotherapy was administered, a granulomatous mass continued to develop. This aggressive growth led to survival of the tumor. Secondary debulking surgery was performed to improve the patient's quality of life at the request of the patient. Using a tissue sample derived from the secondary debulking surgery, we performed an analysis of the tumor's cell surface antigens, differentiation potential, metastatic ability, and inhibition potential by anticancer reagents. In vitro analysis revealed that the cell population grown under adherent culture conditions expressed the mesenchymal stem cell (MSC) markers CD73, CD90, and CD105. The cell line established from this SpCC contained colony-forming unit fibroblasts (CFU-Fs) and exhibited multipotent differentiation into several mesenchymal lineages, including bone, cartilage, and fat. The SpCC cells also displayed vigorous mobilization. These characteristics suggested that they had the differentiation potential of mesenchymal cells, especially MSCs, rather than that of epithelial cells. The surgical specimen analyzed in this study resisted the molecular target reagent cetuximab, which is an epidermal growth factor receptor inhibitor. This clinical insight revealed that chemotherapy-resistant SpCC cells have different characteristics compared to most other cancer cells, which are sensitive to cetuximab. Our cell death assay revealed that SpCC cell death was induced by the anticancer drug imatinib, which is known to inhibit protein tyrosine kinase activity of ABL, platelet-derived growth factor receptor α (PDGFRα), and KIT. Here, we report recurrent SpCC with characteristics of MSCs and potential for treatment with imatinib.
Collapse
Affiliation(s)
- T Ouchi
- 1 Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan.,2 Department of Physiology, Keio University School of Medicine, Tokyo, Japan
| | - S Morikawa
- 1 Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan.,2 Department of Physiology, Keio University School of Medicine, Tokyo, Japan
| | - S Shibata
- 2 Department of Physiology, Keio University School of Medicine, Tokyo, Japan
| | - M Takahashi
- 1 Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan
| | - M Yoshikawa
- 1 Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan.,3 Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
| | - T Soma
- 1 Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan
| | - H Miyashita
- 1 Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan
| | - W Muraoka
- 1 Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan
| | - K Kameyama
- 4 Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan
| | - H Kawana
- 1 Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan
| | - Y Arima
- 3 Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
| | - H Saya
- 3 Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
| | - H Okano
- 2 Department of Physiology, Keio University School of Medicine, Tokyo, Japan
| | - T Nakagawa
- 1 Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan
| | - S Asoda
- 1 Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
32
|
Shibata S. Theoretical Considerations on the Health Checkup Accuracy of Combination Testing. Methods Inf Med 2018. [DOI: 10.1055/s-0038-1634438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary
Objectives:
To find basic theoretical evidence for an optimum combination of multi-phasic health checkup testing obtained by considering how the health checkup accuracy changes with the number of tests (n) and kinds of combination methods (A, B, C, D and E).
Methods:
To find how the health checkup accuracy changes with the number of tests and type of combination method, generalized formulas as functions of the number of tests, are obtained to calculate the over-all health checkup accuracy which is defined by sensitivity ( ), specificity ( ) and odds-ratio ( ), based on the two-by-two table. Five kinds of combination methods were considered: A) Sequential tests. B) Sequential tests after changing the order in A. C) Simultaneous tests using the Believe-the-Negative Rule. D) Simultaneous tests using the Believe-the-Positive Rule. E) Simultaneous tests using the Believe-all-Positive-all-Negative Rule.
Results:
It was provend that combination methods A, B and C are “equivalent” for health checkup accuracy. Therefore, the five methods could be summarized into three patterns. For A, B and C:andincreased but a decreased with increasing n. For D:increased butanddecreased with n. For E:,andincreased with n.
Conclusion:
Health checkup accuracy of combination testing is the best in case of E, although problems exist concerning how to judge the borderline subjects.
Collapse
|
33
|
Shibata S, Ohtuka Y, Hattori M, Aoshima T, Tohyama S, Uchiyama A, Kashihara H, Tamura M, Tsuchiya A, Yoshida K, Sasamori N, Tanaka Y. Subjective Symptoms Acquisition System in a Health Promotion System for the Elderly. Methods Inf Med 2018. [DOI: 10.1055/s-0038-1634334] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
AbstractA previous report was concerned with the evaluation of quality of life using a Health Promotion System for the Elderly. In the present report, we describe one part of that system: a subjective symptoms acquisition and reporting system.The main purpose of this system is to permit any physician or nurse to uniformly employ questionnaires to acquire accurate subjective symptoms. This system is applied in three steps. First, the subjective answers to 21 questions displayed on a personal computer are obtained. These answers correspond to the basic subjective symptoms. Second, if a basic subjective symptom is “positive”, more detailed questions are automatically generated. Finally, clear sentences regarding subjective symptoms are generated and output as a “finding report”.This information is helpful to physicians and nurses in their health-counseling work. An artificial intelligence (AI) program based on “XpertRule” produces detailed questions which are generated by an interactive questionnaire using branching logical rules.
Collapse
|
34
|
Nemoto O, Hirose K, Shibata S, Li K, Kubo H. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study. Br J Dermatol 2018; 178:689-696. [DOI: 10.1111/bjd.16236] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/04/2017] [Indexed: 12/18/2022]
Affiliation(s)
| | - K. Hirose
- Janssen Pharmaceutical K.K.; Tokyo Japan
| | - S. Shibata
- Janssen Pharmaceutical K.K.; Tokyo Japan
| | - K. Li
- Janssen Research and Development, LLC; Spring House PA U.S.A
| | - H. Kubo
- Janssen Pharmaceutical K.K.; Tokyo Japan
| |
Collapse
|
35
|
Mizojiri R, Nakata D, Satoh Y, Morishita D, Shibata S, Iwatani-Yoshihara M, Kosugi Y, Kosaka M, Takeda J, Sasaki S, Takami K, Fukuda K, Kamaura M, Sasaki S, Arai R, Cary DR, Imaeda Y. Discovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1 H)-one Derivatives as Orally eIF4A3-Selective Inhibitors. ACS Med Chem Lett 2017; 8:1077-1082. [PMID: 29057054 DOI: 10.1021/acsmedchemlett.7b00283] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Accepted: 09/08/2017] [Indexed: 12/24/2022] Open
Abstract
Starting from our previous eIF4A3-selective inhibitor 1a, a novel series of (piperazine-1-carbonyl)pyridin-2(1H)-one derivatives was designed, synthesized, and evaluated for identification of orally bioavailable probe molecules. Compounds 1o and 1q showed improved physicochemical and ADMET profiles, while maintaining potent and subtype-selective eIF4A3 inhibitory potency. In accord with their promising PK profiles and results from initial in vivo PD studies, compounds 1o and 1q showed antitumor efficacy with T/C values of 54% and 29%, respectively, without severe body weight loss. Thus, our novel series of compounds represents promising probe molecules for the in vivo pharmacological study of selective eIF4A3 inhibition.
Collapse
Affiliation(s)
- Ryo Mizojiri
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Daisuke Nakata
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshihiko Satoh
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Daisuke Morishita
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Sachio Shibata
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | | | - Yohei Kosugi
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Mai Kosaka
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Junpei Takeda
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Shigekazu Sasaki
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Kazuaki Takami
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Koichiro Fukuda
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Masahiro Kamaura
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Shinobu Sasaki
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Ryosuke Arai
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Douglas R. Cary
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| | - Yasuhiro Imaeda
- Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
36
|
Ishii T, Okai T, Iwatani-Yoshihara M, Mochizuki M, Unno S, Kuno M, Yoshikawa M, Shibata S, Nakakariya M, Yogo T, Kawamoto T. CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens. Sci Rep 2017; 7:13000. [PMID: 29026104 PMCID: PMC5638916 DOI: 10.1038/s41598-017-12513-1] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Accepted: 09/12/2017] [Indexed: 12/21/2022] Open
Abstract
The proof of target engagement (TE) is a key element for evaluating potential investment in drug development. The cellular thermal shift assay (CETSA) is expected to facilitate direct measurement of intracellular TE at all stages of drug development. However, there have been no reports of applying this technology to comprehensive animal and clinical studies. This report demonstrates that CETSA can not only quantitatively evaluate the drug-TE in mouse peripheral blood, but also confirm TE in animal tissues exemplified by using the receptor interacting protein 1 kinase (RIPK1) lead compound we have developed. Our established semi-automated system allows evaluation of the structure-activity relationship using native RIPK1 in culture cell lines, and also enables estimation of drug occupancy ratio in mouse peripheral blood mononuclear cells. Moreover, optimized tissue homogenisation enables monitoring of the in vivo drug-TE in spleen and brain. Our results indicate that CETSA methodology will provide an efficient tool for preclinical and clinical drug development.
Collapse
Affiliation(s)
- Tsuyoshi Ishii
- Biomolecular Research Laboratories, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
| | - Takuro Okai
- Immunology Unit, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Misa Iwatani-Yoshihara
- Biomolecular Research Laboratories, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Manabu Mochizuki
- Biomolecular Research Laboratories, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Satoko Unno
- Immunology Unit, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Masako Kuno
- Immunology Unit, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Masato Yoshikawa
- Immunology Unit, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Sachio Shibata
- Drug Metabolism & Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Masanori Nakakariya
- Drug Metabolism & Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Takatoshi Yogo
- Immunology Unit, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Tomohiro Kawamoto
- Biomolecular Research Laboratories, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
| |
Collapse
|
37
|
Shibata S, Inamoto Y, Saitoh E, Kagaya H, Aoyagi Y, Ota K, Akahori R, Fujii N, Palmer JB, González-Fernández M. The effect of bolus volume on laryngeal closure and UES opening in swallowing: Kinematic analysis using 320-row area detector CT study. J Oral Rehabil 2017; 44:974-981. [PMID: 28891595 DOI: 10.1111/joor.12573] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/06/2017] [Indexed: 01/09/2023]
Abstract
This study investigated the effects of three different volumes of honey-thick liquid on the temporal characteristics of swallowing. Twenty-six healthy subjects (15 males, 11 females) underwent 320-row area detector CT scan while swallowing 3, 10 and 20 mL of honey-thick liquid barium. Three-dimensional images were created at 10 images/s. Kinematic events involving six structures (velopharynx, hyoid bone, epiglottis, laryngeal vestibule (LV), true vocal cords (TVC), upper esophageal sphincter (UES)) and timing of bolus movement were timed using frame by frame analysis. The overall sequence of events did not differ across three volumes; however, increasing bolus volume significantly changed the onset and termination of events. The bolus head reached to pharynx and esophagus earlier and the duration of bolus passing through UES was significantly longer in 10 and 20 mL compared to 3 mL (P < .05). Consequently, the onset of UES opening was significantly earlier with increased volume (P < .05). LV and TVC closure occurred later in 20 mL compared to 3 mL (P < .05). These changes in motion of pharynx and larynx appeared to promote swallow safety by preventing aspiration, suggesting that anatomical structure movements adapt in response to bolus volume. Our findings also suggest that the pharyngeal swallow behaviours may be modified by afferents in the oral cavity. The three-dimensional visualization and quantitative measurements provided by 320-ADCT provide essential benchmarks for understanding swallowing, both normal and abnormal.
Collapse
Affiliation(s)
- S Shibata
- Department of Rehabilitation Medicine I, School of Medicine, Fujita Health University, Toyoake, Japan
| | - Y Inamoto
- Department of Rehabilitation Medicine I, School of Medicine, Fujita Health University, Toyoake, Japan.,Faculty of Rehabilitation, School of Health Sciences, Fujita Health University, Toyoake, Japan
| | - E Saitoh
- Department of Rehabilitation Medicine I, School of Medicine, Fujita Health University, Toyoake, Japan
| | - H Kagaya
- Department of Rehabilitation Medicine I, School of Medicine, Fujita Health University, Toyoake, Japan
| | - Y Aoyagi
- Department of Rehabilitation Medicine I, School of Medicine, Fujita Health University, Toyoake, Japan
| | - K Ota
- Faculty of Rehabilitation, School of Health Sciences, Fujita Health University, Toyoake, Japan
| | - R Akahori
- Department of Rehabilitation Medicine I, School of Medicine, Fujita Health University, Toyoake, Japan
| | - N Fujii
- Department of Radiology, School of Medicine, Fujita Health University, Toyoake, Japan
| | - J B Palmer
- Department of Physical Medicine and Rehabilitation, Johns Hopkins University, Baltimore, MD, USA
| | - M González-Fernández
- Department of Physical Medicine and Rehabilitation, Johns Hopkins University, Baltimore, MD, USA
| |
Collapse
|
38
|
Nakamura T, Kon Y, Konuma K, Sanada T, Shibata S, Gonda H, Suto Y, Amagasa Y, Suzuki A, Fukuda M, Aoyagi C. Gastric cancer detected after Helicobacter pylori eradication at one private screening center in Japan. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx383.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Kim E, Nakamura T, Konno A, Uwamino Y, Nakanishi N, Imamura M, Nakao N, Shibata S, Tanaka S. Measurements of Neutron Spallation Cross Sections of12C and209Bi in the 20- to 150-MeV Energy Range. NUCL SCI ENG 2017. [DOI: 10.13182/nse98-a1977] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- E. Kim
- Tohoku University, Cyclotron and Radioisotope Center, Aoba, Aramaki, Aoba-ku, Sendai 980, Japan
| | - T. Nakamura
- Tohoku University, Cyclotron and Radioisotope Center, Aoba, Aramaki, Aoba-ku, Sendai 980, Japan
| | - A. Konno
- Tohoku University, Cyclotron and Radioisotope Center, Aoba, Aramaki, Aoba-ku, Sendai 980, Japan
| | - Y. Uwamino
- Institute of Physical and Chemical Research, Hirosawa, Wako, Saitama 351-01, Japan
| | - N. Nakanishi
- Institute of Physical and Chemical Research, Hirosawa, Wako, Saitama 351-01, Japan
| | - M. Imamura
- University of Tokyo, Institute for Nuclear Study, 3-2-1, Midori-cho, Tanashi, Tokyo 188, Japan
| | - N. Nakao
- University of Tokyo, Institute for Nuclear Study, 3-2-1, Midori-cho, Tanashi, Tokyo 188, Japan
| | - S. Shibata
- University of Tokyo, Institute for Nuclear Study, 3-2-1, Midori-cho, Tanashi, Tokyo 188, Japan
| | - S. Tanaka
- Japan Atomic Energy Research Institute, Takasaki Research Establishment 1233 Watanuki-cho, Takasaki, Gunma 370-12, Japan
| |
Collapse
|
40
|
Sakamoto M, Shibata S, Asahina R, Yamazoe K, Kamishina H, Ishigaki K, Asano K, Maeda S. Contrast-enhanced ultrasonographic findings of hepatic arterioportal fistulas in a dog. J Small Anim Pract 2017; 58:419. [PMID: 28466480 DOI: 10.1111/jsap.12687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Revised: 08/31/2016] [Accepted: 10/05/2016] [Indexed: 11/27/2022]
Affiliation(s)
- M Sakamoto
- Department of Veterinary Medicine, Faculty of Applied -Biological Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
| | - S Shibata
- Department of Veterinary Medicine, Faculty of Applied -Biological Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
| | - R Asahina
- Department of Veterinary Medicine, Faculty of Applied -Biological Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
| | - K Yamazoe
- Department of Veterinary Medicine, Faculty of Applied -Biological Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
| | - H Kamishina
- Department of Veterinary Medicine, Faculty of Applied -Biological Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
| | - K Ishigaki
- Laboratory of Veterinary Surgery, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, 1866 Kameino, Fujisawa, 252-0880, Japan
| | - K Asano
- Laboratory of Veterinary Surgery, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, 1866 Kameino, Fujisawa, 252-0880, Japan
| | - S Maeda
- Department of Veterinary Medicine, Faculty of Applied -Biological Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
| |
Collapse
|
41
|
Hau CS, Shimizu T, Tada Y, Takeoka S, Shibata S, Mitsui A, Kamata M, Asano Y, Sugaya M, Kadono T, Sato S, Watanabe S. 023 The vitamin D3 analog, maxacalcitol, ameliorates imiquimod induced murine psoriasiform skin inflammation by inducing regulatory T cells and downregulating Th17 responses. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Abstract
SUMMARY
Composite resin may make a restoration noticeable as time passes, on account of its color instability. The repair technique is a minimally invasive treatment for class IV composite resin restorations that show unsatisfactory coloration. Thus, the objective of the present article was to report a clinical case involving a conservative technique used for repairing a class IV composite resin restoration in the left maxillary central incisor and the replacement of a class IV restoration in the right maxillary central incisor.
Collapse
Affiliation(s)
- VC Ruschel
- Vanessa Carla Ruschel, DDS, MSD, PHD, Federal University of Santa Catarina, Operative Dentistry, Florianopolis, Brazil
| | - SC Stolf
- Sheila Cristina Stolf, DDS, MS, PhD, Federal University of Santa Catarina, Operative Dentistry, Florianopolis, Brazil
| | - S Shibata
- Shizuma Shibata, DDS, MSD, PhD, Federal University of Santa Catarina, Operative Dentistry, Florianópolis, Brazil
| | - LN Baratieri
- Luiz Narciso Baratieri, DDS, MSD, PhD, Federal University of Santa Catarina, Operative Dentistry, Florianopolis, Brazil
| |
Collapse
|
43
|
Jin ZW, Abe H, Jin Y, Shibata S, Murakami G, Rodríguez-Vázquez JF. Positional changes in tendon insertions from bone to fascia: development of the pes anserinus and semimembranosus muscle insertion in human foetuses. Folia Morphol (Warsz) 2016; 75:503-511. [DOI: 10.5603/fm.a2016.0020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2016] [Accepted: 03/04/2016] [Indexed: 11/25/2022]
|
44
|
Mohanty PK, Arunbabu KP, Aziz T, Dugad SR, Gupta SK, Hariharan B, Jagadeesan P, Jain A, Morris SD, Rao BS, Hayashi Y, Kawakami S, Oshima A, Shibata S, Raha S, Subramanian P, Kojima H. Transient Weakening of Earth's Magnetic Shield Probed by a Cosmic Ray Burst. Phys Rev Lett 2016; 117:171101. [PMID: 27824449 DOI: 10.1103/physrevlett.117.171101] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Indexed: 06/06/2023]
Abstract
The GRAPES-3 tracking muon telescope in Ooty, India measures muon intensity at high cutoff rigidities (15-24 GV) along nine independent directions covering 2.3 sr. The arrival of a coronal mass ejection on 22 June 2015 18:40 UT had triggered a severe G4-class geomagnetic storm (storm). Starting 19:00 UT, the GRAPES-3 muon telescope recorded a 2 h high-energy (∼20 GeV) burst of galactic cosmic rays (GCRs) that was strongly correlated with a 40 nT surge in the interplanetary magnetic field (IMF). Simulations have shown that a large (17×) compression of the IMF to 680 nT, followed by reconnection with the geomagnetic field (GMF) leading to lower cutoff rigidities could generate this burst. Here, 680 nT represents a short-term change in GMF around Earth, averaged over 7 times its volume. The GCRs, due to lowering of cutoff rigidities, were deflected from Earth's day side by ∼210° in longitude, offering a natural explanation of its night-time detection by the GRAPES-3. The simultaneous occurrence of the burst in all nine directions suggests its origin close to Earth. It also indicates a transient weakening of Earth's magnetic shield, and may hold clues for a better understanding of future superstorms that could cripple modern technological infrastructure on Earth, and endanger the lives of the astronauts in space.
Collapse
Affiliation(s)
- P K Mohanty
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India†
| | - K P Arunbabu
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India†
| | - T Aziz
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India†
| | - S R Dugad
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India†
| | - S K Gupta
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India†
| | - B Hariharan
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India†
| | - P Jagadeesan
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India†
| | - A Jain
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India†
| | - S D Morris
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India†
| | - B S Rao
- Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400005, India†
| | - Y Hayashi
- Graduate School of Science, Osaka City University, 558-8585 Osaka, Japan†
| | - S Kawakami
- Graduate School of Science, Osaka City University, 558-8585 Osaka, Japan†
| | - A Oshima
- College of Engineering, Chubu University, Kasugai, Aichi 487-8501, Japan†
| | - S Shibata
- College of Engineering, Chubu University, Kasugai, Aichi 487-8501, Japan†
| | - S Raha
- Bose Institute, 93/1, A.P.C. Road, Kolkata 700009, India†
| | - P Subramanian
- Indian Institute of Science Education and Research, Pune 411021, India†
| | - H Kojima
- Faculty of Engineering, Aichi Institute of Technology, Toyota City, Aichi 470-0392, Japan†
| |
Collapse
|
45
|
Nakamura T, Kon Y, Shibata S, Konuma K, Sanada T, Gonda H, Suto Y, Kobayashi K, Takita N, Shimura M, Yoshida H, Suzuki A, Onuki S, Fukuda M, Aoyagi C, Hasegawa Y, Nishiwaki A. Duodenal neoplasm in screening esophagogastroduodenoscopy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw385.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
Jin ZW, Shibata S, Abe H, Jin Y, Li XW, Murakami G. A new insight into the fabella at knee: the foetal development and evolution. Folia Morphol (Warsz) 2016; 76:87-93. [PMID: 27665955 DOI: 10.5603/fm.a2016.0048] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Revised: 08/09/2016] [Accepted: 08/09/2016] [Indexed: 11/25/2022]
Abstract
Using longitudinal semiserial sections of 12 lower extremities from 8 human foetuses at 15-18 weeks, we compared foetal morphologies of the knee in specimens with and without fabellae. We also compared the fabella, if present, with the hallucal sesamoid in the same foetus. Cartilaginous fabella, positive for versican and tenascin by immunohistochemistry, was found in 5 of the 8 foetuses. This structure was embedded in a thick and tight lateral fibrous band, providing a common origin of the plantaris muscle and the lateral head of the gastrocnemius muscle. The plantaris was covered by the lateral head of the gastrocnemius, but these 2 muscles were separated by a distinct fascia or space. Notably, the foetal fabella did not attach to the joint capsule. In the 3 specimens without fabellae, the lateral fibrous band was thin, containing a fibrous mass, negative for versican and tenascin, in place of the fabella. The "medial" head of the gastrocnemius faced or covered the plantaris, while the lateral head was continuous with the plantaris. A hallucal cartilaginous sesamoid, positive for versican and tenascin, was present in all 8 specimens. It carried a flat surface facing the joint cavity and was covered by tendons of the short muscles of the foot. Because of the difference in topographical relation of muscles between specimens with or without fabella, rather than mechanical stress to the tendon, fabella development may require a distinct plantaris muscle independent of the gastrocnemius. We discussed about an evolutionary aspect of the fabella and plantaris muscle.
Collapse
Affiliation(s)
- Z W Jin
- Department of Anatomy, Histology and Embryology, Yanbian University Medical College, Yanji, China.
| | | | | | | | | | | |
Collapse
|
47
|
Oka T, Sugaya M, Takahashi N, Takahashi T, Shibata S, Miyagaki T, Asano Y, Sato S. 243 CXCL17 Attenuates imiquimod-induced Psoriasis-like skin inflammation by recruiting myeloid-derived suppressor cells and regulatory T cells. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
48
|
Shibata S, Taguchi CMC, Gondo R, Stolf SC, Baratieri LN. Ceramic Veneers and Direct-Composite Cases of Amelogenesis Imperfecta Rehabilitation. Oper Dent 2016; 41:233-42. [DOI: 10.2341/15-079-t] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
SUMMARY
The aim of this article is to present two case reports for the treatment of patients affected with amelogenesis imperfecta. One case was treated with composite resin and the other case with ceramic veneers. Esthetic and functional results were achieved using both treatments, and a review of advantages and disadvantages is presented.
Collapse
Affiliation(s)
- S Shibata
- Shizuma Shibata, DDS, MS, Operative Dentistry, Federal University of Santa Catarina (UFSC), Florianópolis, Santa Catarina, Brazil
| | - CMC Taguchi
- Carolina Mayumi Cavalcanti Taguchi, DDS, MS, Operative Dentistry, Federal University of Santa Catarina (UFSC), Florianopolis, Santa Catarina, Brazil
| | - R Gondo
- Renata Gondo, DDS, PhD, Operative Dentistry, Universidade Federal de Santa Catarina (UFSC), Florianopolis, Santa Catarina, Brazil
| | - SC Stolf
- Sheila Cristina Stolf, DDS, PhD, Operative Dentistry, Universidade Federal de Santa Catarina (UFSC), Florianopolis, Brazil
| | - LN Baratieri
- Luiz Narciso Baratieri, DDS, PhD, Operative Dentistry, Universidade Federal de Santa Catarina (UFSC), Florianopolis, Brazil
| |
Collapse
|
49
|
Sato Y, Maeda Y, Minami H, Yasukawa Y, Yamamoto K, Tamamura H, Shibata S, Bou S, Sasaki M, Tameshige Y, Ooto H, Kasahara S, Shimizu Y, Saga Y, Omoya A, Saito M, Aoyama M. Daily Dose Evaluation Utilizing In-Room Computed Tomography Positioning System for Prostate Cancer Treatment in Proton Therapy. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
50
|
Sakiyama Y, Shibata S, Sanayama H, Ono S, Maekawa M, Matsuo M, Irie T, Eto Y. Intrathecal 2-Hydroxypropyl-Beta-Cyclodextrin (HPBCD) therapy in adult-onset Niemann-Pick Disease Type C (NPC). J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|